{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:17Z","timestamp":1791262457724,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The group therapy model has been recently favored as a means of conducting psychedelic assisted therapies for mental health disorders. However, there is a paucity of literature showing strengths or drawbacks of this approach and comparisons of safety and efficacy to individual therapy. This systematic review aims to address this gap in literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included original research of group psychedelic therapy programs that were peer reviewed and published in English or where a translation was available or possible. Participants must be 18 or older and have a psychiatric diagnosis. We searched for MEDLINE, Scopus, and APA PsychInfo until January 1 2026. Screening, data extraction, and appraisal using the Mixed Methods Appraisal Tool (MMAT) were conducted by two independent researchers. A parallel-results convergent synthesis design was employed consisting of independent syntheses of qualitative and quantitative evidence and an interpretation of the results in the discussion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 30 papers representing 22 unique group therapy protocols. Demographics were inconsistently reported: sex or gender was reported in 18 papers, race\/ethnicity in eight papers. Fifteen papers reported pre\u2013post outcomes using validated screening tools for mental health, functioning, substance use, or wellbeing. Using a segregated methodologies approach, quantitative and qualitative findings were broadly complementary. Quantitative results showed overall decreases in validated scale outcomes reflecting improvement in depression, anxiety, trauma symptoms, functioning, and other psychiatric outcomes. Qualitative results described improvements in mindfulness, emotional processing, psychological flexibility, meaning-making, and social connectedness supported by the group format.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite emerging mechanistic evidence for direct effects of psychedelic molecules on the brain, only a minority of studies used comparison groups, and only one was a modern randomized controlled trial. Group PaT may not only be pragmatically beneficial for feasibility and cost-effectiveness, but may also contribute to therapeutic outcomes through peer support, normalization, belonging, and integration. Limitations of this systematic review include substantial heterogeneity in molecules, populations, protocols, outcome measures, and follow-up duration, as well as overlapping cohorts and few studies with group components throughout the entire course of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO:\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024491478<\/jats:ext-link>\n                      , identifier: CRD42024492648.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1788352","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:23Z","timestamp":1791260723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Vivian W. L.","family":"Tsang","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Evidence-based healthcare, Department of Continuing Education, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ferrey","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hartmann-Boyce","sequence":"additional","affiliation":[{"name":"School of Public Health and Health Sciences, University of Massachusetts Amherst","place":["Amherst, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1016\/j.addicn.2022.100025","article-title":"Classic and non-classic psychedelics for substance use disorder: a review of their historic, past and current research","volume":"3","author":"Mendes","year":"2022","journal-title":"Addict Neurosci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"868103","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward synergies of ketamine and psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front Psychol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review","volume":"8","author":"Walsh","year":"2021","journal-title":"BJPsych Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/02791072.2020.1817639","article-title":"Efficacy of psychoactive drugs for the treatment of posttraumatic stress disorder: a systematic review of MDMA, ketamine, LSD and psilocybin","volume":"53","author":"Varker","year":"2020","journal-title":"J Psychoactive Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA and ketamine","volume":"41","author":"De Gregorio","year":"2021","journal-title":"J Neurosci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"109165","DOI":"10.1016\/j.neuropharm.2022.109165","article-title":"Novel ethical and policy issues in psychiatric uses of psychedelic substances","volume":"216","author":"Smith","year":"2022","journal-title":"Neuropharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD012880","DOI":"10.1002\/14651858.CD012880.pub2","article-title":"Alcoholics anonymous and other 12-step programs for alcohol use disorder","volume":"11","author":"Kelly","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.psyche.2026.100009","article-title":"Exploring patterns of concurrent substance use, psychedelic dosing and intentions, and childhood trauma in psychedelic use in college-aged adults","volume":"3","author":"Tsang","year":"2026","journal-title":"Psychedelics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40337-022-00588-9","article-title":"A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders","volume":"10","author":"Robison","year":"2022","journal-title":"J Eat Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"803279","DOI":"10.3389\/fpsyt.2021.803279","article-title":"A cohort-based case report: the impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression","volume":"12","author":"Dames","year":"2022","journal-title":"Front Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-assisted group therapy: a systematic review","volume":"51","author":"Trope","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/2054.2022.00222","article-title":"Group format psychedelic-assisted therapy interventions: observations and impressions from the HOPE trial","volume":"7","author":"Lewis","year":"2023","journal-title":"J Psychedelic Stud"},{"key":"B15","doi-asserted-by":"publisher","first-page":"20451253231171512","DOI":"10.1177\/20451253231171512","article-title":"Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review","volume":"13","author":"Tsang","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manage"},{"key":"B17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/02791072.2023.2253798","article-title":"A pilot study comparing a community of practice program with and without concurrent ketamine-assisted therapy","volume":"56","author":"Tsang","year":"2024","journal-title":"J Psychoactive Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1097\/JOM.0000000000003579","article-title":"Ketamine-assisted therapy outcomes for first responders with comorbid mental health diagnoses","volume":"68","author":"Tsang","year":"2026","journal-title":"J Occup Environ Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1097\/JOM.0000000000003352","article-title":"The effect of ketamine-assisted group therapy on treatment-resistant mental health conditions in firefighters: a prospective observational case series","volume":"67","author":"Tsang","year":"2025","journal-title":"J Occup Environ Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/cncr.35024","article-title":"Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: qualitative analysis","volume":"130","author":"Beaussant","year":"2024","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20451253251383415","article-title":"Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders","volume":"15","author":"Flynn","year":"2025","journal-title":"Ther Adv Psychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/psymed.2024.0050","article-title":"Ketamine-assisted group therapy for work-related stress in first responders and Frontline Health Care Workers","volume":"28","author":"Flynn","year":"2025","journal-title":"Psychedelic Med."},{"key":"B24","first-page":"56","article-title":"Observations regarding the use of LSD-25 in the treatment of alcoholism","volume":"1","author":"Cheek","year":"1966","journal-title":"J Psychopharmacol."},{"key":"B25","article-title":"Psycholytic therapy with MDMA and LSD in Switzerland","author":"Gasser","year":"1995","journal-title":"MAPS Bull."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.15288\/qjsa.1962.23.315","article-title":"A treatment program for alcoholics in a mental hospital","author":"Jensen","year":"1961","journal-title":"Q J Stud Alcohol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1024\/0939-5911\/a000956","article-title":"Psilocybin-assistierte Gruppenpsychotherapie bei Abh\u00e4ngigkeitserkrankungen: Erfahrungen aus drei Jahren Methodenentwicklung an der Klinik S\u00fcdhang","volume":"71","author":"Wopfner","year":"2025","journal-title":"Sucht."},{"key":"B28","doi-asserted-by":"publisher","first-page":"863552","DOI":"10.3389\/fpsyt.2022.863552","article-title":"Using an MDMA- and LSD-group therapy model in clinical practice","volume":"13","author":"Oehen","year":"2022","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1192\/bjp.109.458.37","article-title":"Permissive group therapy with lysergic acid diethylamide","volume":"109","author":"Spencer","year":"1963","journal-title":"Br J Psychiatry."},{"key":"B30","first-page":"41","article-title":"Difficulties in psychotherapy with psychodysleptics","volume":"4","author":"Sokolik","year":"1972","journal-title":"World J Psychosynthesis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e35889","DOI":"10.1002\/cncr.35889","article-title":"Long-term benefits of single-dose psilocybin in depressed patients with cancer","volume":"131","author":"Agrawal","year":"2025","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1004519","DOI":"10.1371\/journal.pmed.1004519","article-title":"Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: a randomized controlled trial","volume":"22","author":"Lewis","year":"2025","journal-title":"PLoS Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","article-title":"Use of d-lysergic acid diethylamide in the treatment of alcoholism","volume":"20","author":"Chwelos","year":"1959","journal-title":"Q J Stud Alcohol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism: effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q J Stud Alcohol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2024.00401","article-title":"Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico","author":"Giovannetti","year":"2024","journal-title":"J Psychedelic Stud"},{"key":"B36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000285664","article-title":"Group and individual psychotherapy under LSD","volume":"11","author":"Hausner","year":"1963","journal-title":"Acta Psychother Psychosom."},{"key":"B37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/00221678211022949","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis","volume":"64","author":"Agin-Liebes","year":"2024","journal-title":"J Humanist Psychol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.15288\/jsad.23-00005","article-title":"Ayahuasca Treatment Outcome Project (ATOP): one-year results from Takiwasi Center and implications for psychedelic science","volume":"85","author":"Rush","year":"2024","journal-title":"J Stud Alcohol Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/02791072.2023.2186285","article-title":"Ketamine-assisted group psychotherapy for frontline healthcare workers with COVID-19-related burnout and PTSD: a case series of effectiveness\/safety for 10 participants","volume":"56","author":"Robison","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abuse Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1727487","DOI":"10.3389\/fpsyt.2025.1727487","article-title":"Ketamine-assisted group psychotherapy integrating cognitive processing therapy to address identity-based trauma: a pilot study","volume":"16","author":"Sevelius","year":"2026","journal-title":"Front Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/02698811231155117","article-title":"Can psychedelics enhance group psychotherapy?","volume":"37","author":"Ponomarenko","year":"2023","journal-title":"J Psychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"20451253231198466","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"24com15504","DOI":"10.4088\/JCP.24com15504","article-title":"Functional unblinding in pivotal studies and the future of psychedelic medicine","volume":"85","author":"Rosenbaum","year":"2024","journal-title":"J Clin Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/02791072.2023.2223195","article-title":"Psilocybin's potential mechanisms in the treatment of depression: a systematic review","volume":"56","author":"Lee","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/g8s7c","article-title":"Changes in the breadth of visual-spatial attention affect subsequent mood","author":"Hanif","year":"2020","journal-title":"PsyArXiv"},{"key":"B49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.genhosppsych.2010.10.002","article-title":"Efficacy of peer support interventions for depression: a meta-analysis","volume":"33","author":"Pfeiffer","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/sjop.12376","article-title":"Seeing the big picture: broadening attention relieves sadness","volume":"58","author":"Gu","year":"2017","journal-title":"Scand J Psychol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1788352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:26Z","timestamp":1791260726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1788352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":50,"alternative-id":["10.3389\/fpubh.2026.1788352"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1788352","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1788352"}}